Histogen Inc. (HSTO) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 San Diego, CA, 美国. 现任CEO为 Susan A. Knudson.
HSTO 拥有 IPO日期为 2013-07-25, 7 名全职员工, 在 NASDAQ Capital Marke, 市值为 $85.44K.
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
